NEW YORK (GenomeWeb News) – Vermillion yesterday reported minimal revenues for the fourth quarter of 2007, accompanied by a wider net loss, as it continues to take steps to launch its first diagnostic tests later this year.
Vermillion reiterated in its financial report that it “anticipates no major revenue until its diagnostic tests are commercialized” due to the sale of its proteomics tools business to Bio-Rad in November 2006.  

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.